Repligen reports Q3 adjusted EPS 46c, consensus 42c

Reports Q3 revenue $188.766M, consensus $181.72M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We had another outstanding quarter in Q3 with 18% organic growth. We are thrilled with the momentum we are seeing across our broad, differentiated portfolio and the continued execution by our team. This resulted in double-digit revenue growth across all franchises and geographies. Consumables and capital equipment revenues were strong again, with continued performance from biopharma and CDMOs.”